KYMR Kymera Therapeutics, Inc.
KYMR Kymera Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 2 scans as of 2026-10-16 2 neutral converging
POC $84.86 · VWAP $90.82 · +15.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
3 watchlists
KYMR Price Structure
Loading timeframes…
Peers
Every watchlist KYMR belongs to, members best 30-day change first — KYMR highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
@monster-discoveries
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-06-30: revenue $65M, diluted EPS -$0.62, net income -$61M (SEC filing). Across the print the stock moved +1.9% (close before → first close after).
full note →Against street estimates
How KYMR's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about KYMR from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 4 days ago · Oct 13
- Kymera Therapeutics Stock Price | KYMR Stock Quote, News, and History | Markets Insider
- Kymera Therapeutics Stock Price | KYMR Stock Quote, News, and History | Markets Insider
- Kymera Therapeutics (Nasdaq:KYMR) - Análisis de acciones - Simply Wall St
- Kymera Therapeutics Inc Stock Price Today | NASDAQ: KYMR Live - Investing.com
- Press Releases | Kymera Therapeutics, Inc.
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
KYMR research tape
92 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to KYMR.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries